Sanotize is recruiting for a COVID trial in the province of Quebec.   
Sanotize Logo

“To our knowledge,

NITRIC OXIDE

is the only substance shown so far to have a

DIRECT EFFECT

on SARS-CoV-2,”  – Åke Lundkvist*

* D. Akaberi et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biology. September 2020.

SaNOtize is recruiting for a COVID trial in the province of Quebec.

Harnessing the Power of Nitric Oxide to Treat Topical Infections

Our Solution

Utilizing the unique antimicrobial and immunomodulating properties of Nitric Oxide to treat diseases of the respiratory system and the skin.

Our Products

NORSTM, our platform technology, can treat a variety of topical infections. From sinusitis via nasal lavage and the flu via nasal spray, to acne via topical gel.

An update on COVID-19

SaNOtize is working diligently with Health Canada and the FDA to obtain approval for the emergency release of a preventative treatment for healthcare workers and high risk individuals exposed to SARS-CoV-2.

Our Team

Dr. Gilly Regev, PhD and Dr. Chris Miller, PhD, BA, RT are co-founders of SaNOtize.  Dr. Regev and Dr. Miller are among a small group of people who are experts at using nitric oxide therapeutically.   The SaNOtize leadership team is complemented by a number of talented researchers, scientists and accomplished entrepreneurs, and is advised by a distinguished board of directors.

The Latest News

Read our latest Press Releases

 Learn about current initiatives and updates from saNOtize.
logged in